Working with us during COVID-19
Our COVID-19 research
We are using our clinical research resources to lead high priority COVID-19 studies. There is currently no cure for COVID-19. Our research is making potential treatments, vaccines and new developments available to our patients now to help save lives.
We are part of national and international research studies to rapidly develop new treatments and to build and share our knowledge of this virus.
Please find further information about how we are working and prioritising our research during COVID-19 in the drop-down menus below.
If you cannot find the information you are looking for, then please contact us.
Visiting our research facilities
Visiting our facilities
At the start of the pandemic, all routine research inspections, site and monitoring visits were paused.
We recognise that the requirement for transparency, accountability and above all the safety of our research remains of vital importance and so we are putting in place additional risk assessments to enable essential visits to take place from September 2020.
However, please remember that in line with NUH and national guidance, non-essential visits to our hospitals are still restricted and this includes site visits/inspections of our research facilities.
The majority of site visits will continue to be carried out remotely. We are introducing additional equipment to facilitate remote visits.
Face-to-face visits may be possible for essential monitoring purposes. Please discuss this with your Reasearch Team or email us, if you would like more details.
Before arranging a visit, our staff will complete risk assessments of the facilities to be visited.
Visiting Nottingham University Hospitals NHS Trust
Please ensure that you have read and understood the requirements for visitors to NUH, inaddition to any requests made by our Research Teams. The lastest information on visiting our hospitals can be found on the information for visitors pages of this website.
Live trials for COVID-19
COVID-19 clinical trials
We are carrying out a number of trials for patients who are being treated at or admitted to NUH for COVID-19.
Our research is part of the national and international response to COVID-19. Our expert clinical research teams are helping to find the most effective drugs, vaccines and treatments. Our aim is to offer every patient with suspected or confirmed COVID-19 the opportunity to take part in this vital research.
If you are admitted to NUH with suspected or confirmed COVID-19, then your clinical team and our research nurses (who specialise in supporting patients taking part in clinical trials) will talk to you about taking part in COVID-19 studies here.
Recovery from COVID-19
- NoRCoRP - the Nottingham Recovery from COVID-19 Research Platform brings together a number of research projects looking at the impact of COVID-19 and the needs of patients recovering after the infection.
- PHOSP COVID - involves 20 universities and their partner NHS trusts, as well as charity partners AUK-BLF. It aims to recruit 10,000 people, to understand the longer term effects of COVID-19 for patients after they leave hospital.
- Oxford Vaccine Trial - our experts in experimental medicine, based in our NIHR Nottingham Clinical Research Facility, are supporting the first national trial of a vaccine for COVID-19. Taking place at Cripps Health Centre on the University of Nottingham campus, this trial involves frontline health and social care staff aged over 18 years.
- NHS COVID-19 Vaccine Registry - you can sign up to take part in future trials now as part of the national volunteer programme to find an effective vaccine.
Tests for COVID-19
- FALCON - the Facilitating AcceLerated Clinical validation Of novel diagnostics for COVID-19 is a national trial to rapidly assess new diagnostic tests for COVID-19. Nationally the study will assess approximately 10 new tests. Many of those tests are likely to be point of care tests, which can be done at the patient's bedside and which often return results in as little as five minutes
- Using Medical Detection dogs to identify people with COVID-19 - from September 2020 researchers at NUH will join a national trial to test whether sniffer dogs can detect COVID-19
Drug and treatment trials
- RECOVERY - there are no specific treatments for COVID-19. This trial is investigating five different drugs, currently used for other conditions, to see if they have benefits for patients with COVID-19. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and health services with information they need to determine which treatments should be used. Initially for adults, we have now extended this trial at NUH to include newborns, children and young people under the age of 18 years.
- REMAP-CAP – this study is identifying the most clinically effective interventions for adult patients admitted to an intensive care unit with community-acquired pneumonia and COVID-19.
- ACCORD-2 - this is a national trial to fast-track the development of new drugs for treating COVID-19. It is a partnership between the NHS, the pharmaceutical industry and specialist research centres including the NIHR Nottingham Clinical Research Facility based at NUH.
- RECOVERY-RS - this trial is investigating the most effective way to administer oxygen to COVID-19 patients. Methods including CPAP and High Flow Nasal Oxygen (HFNO) are being used, comparing with more commonly used masks and nasal tubes.
- ISARIC - NUH is already part of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) which is working to investigate severe acute respiratory illnesses (SARI). Data from patients at NUH suspected of having, or who are confirmed with, COVID-19 is now being included in this research.
- PRIEST – this study is investigating the most effective ways of triaging people with suspected respiratory infections in emergency care during a pandemic.
- GenOMICC – looking into the genetic susceptibility of patients to COVID-19 in critical care. This trial is aiming to find genetic markers which may help researchers and clinicians to identify patients who are at greater risk.
- PACE - a study investigating the effects of COVID-19 for patients with acute myeloid leukemia (AML).
- COVID-19-BMT - is a study investigating severe COVID-19 infection in allogeneic stem cell recipients. It involves both adults and children of any age who have received allogeneic stem cell transplantation and who have tested positive for COVID-19.
- DIScOVER - comparing disability in activities of daily living for adults with advanced lung cancer or respiratory disease during the COVID-19 pandemic
- EXCEED - led by the NIHR Leicester Biomedical Research Centre and the University of Leicester, this study is calling for volunteers to help understand why some people develop more severe COVID-19 than others – particularly those from black and minority ethnic communities.
Trials for women and babies
- UKOSS - the UK Obstentrics Surveillance System (UKOSS) is collecting data from pregnant women who have a COVID-19 diagnosis to help understand more about how the virus may affect women and infants.
- PAN-COVID - this study is looking at the impacts of COVID-19 on pregnant women and their babies.
- Neonatal complications of COVID-19 - this study is collecting information about newborn babies who have Coronavirus or who are born to mothers who have Coronavirus.
Experiences of COVID-19
- Psychological impact of COVID-19 - this international study is aiming to better understand how Coronavirus and the restrictions necessary to prevent its spread are impacting on our day to day lifestyle. This study is using an online questionnaire and is open to anyone over the age of 16 years.
End of life care
- COV-Pall - a rapid evaluation of the COVID-19 pandemic response in palliative and end of life care.
New ways of working
- COVID-NURSE - is evaluating the impact on patient experience of a combination of nursing innovations. NUH is part of a consortium of universities and NHS trusts, working together to build the evidence that will help nursing teams nationally and internationally to adopt best practice for care during a pandemic.